Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 38 pages | ID: LE41E40D0E44EN
Global Markets Direct

Abstracts

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2022'; Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.

Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as EDG receptors. EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, and smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.

The report 'Lysophosphatidic Acid Receptor 1 - Drugs In Development, 2022' outlays comprehensive information on the Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively. Report covers products from therapy areas Respiratory, Gastrointestinal, Metabolic Disorders, Genito Urinary System And Sex Hormones, Immunology, Musculoskeletal Disorders and Toxicology which include indications Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Pulmonary Fibrosis, Diabetic Neuropathy, Diarrhea, Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Kidney Fibrosis, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and Systemic Sclerosis (Scleroderma).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
• The report reviews Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Overview
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Curadim Pharma Co Ltd
Epigen Biosciences Inc
Horizon Therapeutics Plc
Novo Nordisk AS
RxBio Inc
Takeda Pharmaceutical Co Ltd
Ube Industries Ltd
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Drug Profiles
BMS-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986278 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986337 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CP-2090 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EPGN-2154 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EPGN-696 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HL-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HZN-825 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Rx-100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-615 - Drug Profile
Product Description
Mechanism Of Action
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Dormant Products
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) - Product Development Milestones
Featured News & Press Releases
Jan 24, 2022: Horizon Therapeutics announces first patient enrolled in phase 2b pivotal trial evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis (IPF)
Nov 09, 2021: Horizon Therapeutics announces first patient enrolled in phase 2b pivotal trial evaluating HZN-825 for the treatment of diffuse cutaneous systemic sclerosis
Sep 28, 2011: RxBio Receives $15m BARDA Contract For Development Of Rx100 To Protect Against Radiation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Curadim Pharma Co Ltd, 2022
Pipeline by Epigen Biosciences Inc, 2022
Pipeline by Horizon Therapeutics Plc, 2022
Pipeline by Novo Nordisk AS, 2022
Pipeline by RxBio Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Ube Industries Ltd, 2022
Dormant Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022